AtriCure Enrolls, Treats First Patient In BoxX-NoAF Clinical Study In Orlando, Florida

Author: Benzinga Newsdesk | October 28, 2025 07:08am

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was enrolled and treated in the Box Lesion Creation with Left Atrial Appendage Exclusion to Reduce the Occurrence of New-onset Atrial Fibrillation (BoxX-NoAF) clinical trial (NCT06989775). The first patient was treated by Dr. Anthony Rongione, Cardiothoracic Surgeon at Orlando Health Heart and Vascular Institute in Orlando, Florida.

New onset or post-operative Afib (POAF) is the most common complication following cardiac surgery, occurring in as many as 50% of patients1,2 presenting immediately or in the months following surgery. These arrhythmias are associated with increased mortality, morbidity, cerebrovascular accidents, Afib recurrence, hospital length of stay, and total hospital costs. BoxX-NoAF is a prospective, multicenter, randomized, FDA-approved investigational device exemption (IDE) clinical trial of up to 960 subjects at up to 75 sites worldwide. This seminal trial will ultimately define clinical practice and treatment guidelines for reducing the occurrence of POAF and longer-term clinical Afib in elevated risk cardiac surgery patients.

Posted In: ATRC